What is B. Riley's Forecast for TG Therapeutics Q3 Earnings?

Key Points

• B. Riley has revised its Q3 2025 earnings per share estimate for TG Therapeutics down from $0.27 to $0.25, while maintaining a "Buy" rating and a price target of $55.00.
• The consensus estimate for TG Therapeutics full-year earnings is significantly lower, at just $0.08 per share, indicating cautious expectations for the company's performance.
• The company is experiencing volatility, with its stock currently trading around $32.04, and has a market capitalization of $5.08 billion.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley dropped their Q3 2025 earnings per share estimates for TG Therapeutics in a report released on Wednesday, September 17th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of $0.25 for the quarter, down from their prior estimate of $0.27. B. Riley has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2025 earnings at $0.84 EPS and FY2027 earnings at $2.13 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The company had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company's revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter last year, the business posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS.

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a report on Thursday, July 10th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $48.00.

TG Therapeutics Stock Down 0.7%

NASDAQ:TGTX traded down $0.24 during midday trading on Thursday, reaching $32.37. The company had a trading volume of 3,197,005 shares, compared to its average volume of 2,006,223. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of 87.49 and a beta of 1.88. The stock's fifty day simple moving average is $31.91 and its 200-day simple moving average is $35.65. TG Therapeutics has a 12-month low of $21.16 and a 12-month high of $46.48. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89.

Institutional Trading of TG Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its position in shares of TG Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock worth $898,000 after purchasing an additional 8,338 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of TG Therapeutics by 175.0% during the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock worth $4,746,000 after purchasing an additional 76,600 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of TG Therapeutics during the first quarter worth about $226,000. GAMMA Investing LLC increased its position in shares of TG Therapeutics by 77.7% during the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 1,986 shares in the last quarter. Finally, Braun Stacey Associates Inc. increased its position in shares of TG Therapeutics by 13.5% during the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company's stock worth $19,819,000 after purchasing an additional 59,845 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares of the company's stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.64% of the stock is owned by company insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.